2-Guanidinoquinazolines as new inhibitors of the STAT3 pathway

Bioorganic and Medicinal Chemistry Letters

Volumn 24, Issue 21, 2014, Pages 5081-5085

  Laporte, Matthew G ^a   Da Paz Lima, Dimas José ^a   Zhang, Feng ^a   Sen, Malabika ^b   Grandis, Jennifer R ^b,c   Camarco, Daniel ^a   Hua, Yun ^a   Johnston, Paul A ^a,c   Lazo, John S ^d   Resnick, Lynn O ^a   Wipf, Peter ^a,c   Huryn, Donna M ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Cancer cell line screening; Guanidinoquinazolines; Skraup synthesis; STAT3 pathway; Structure activity relationships

Indexed keywords

2 GUANIDINOQUINAZOLINE DERIVATIVE; ANTINEOPLASTIC AGENT; GAMMA INTERFERON; INTERLEUKIN 6; QUINAZOLINE DERIVATIVE; STAT1 PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; GUANIDINE; PROTEIN BINDING;

AMINATION; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; DRUG SYNTHESIS; HEAD AND NECK SQUAMOUS CELL CARCINOMA; IC50; LUNG CANCER CELL LINE; NON SMALL CELL LUNG CANCER; PROTEIN PHOSPHORYLATION; STRUCTURE ACTIVITY RELATION; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; HUMAN; METABOLISM; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; GUANIDINE; HUMANS; PROTEIN BINDING; QUINAZOLINES; STAT3 TRANSCRIPTION FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84908012116     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2014.09.001     Document Type: Article

References (34)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer Stat. 62 2012 10
2. J.I. Song, and J.R. Grandis Oncogene 19 2000 2489
3. P. Specenier, and J.B. Vermorken Biol. Targets Ther. 7 2013 77
4. D. Hanahan, and R.A. Weinberg Cell 144 2011 646
5. For recent reviews of STAT3 and inhibitors, see: N.D. Peyser, and J.R. Grandis Onco Targets Ther. 6 2013 999
6. B. Debnath, S. Xu, and N. Meamati J. Med. Chem. 55 2012 6645
7. L. Lin, B. Hutzen, M. Zuo, S. Ball, S. Deangelis, E. Foust, B. Pandit, M.A. Ihnat, S.S. Shenoy, S. Kulp, P.-K. Li, C. Li, J. Fuchs, and J. Lin Cancer Res. 70 2010 2445
8. D. Masciocchi, A. Gelain, S. Villa, F. Meneghetti, and D. Barlocco Future Med. Chem. 3 2011 567
9. S.R. Walker, and D.A. Frank JAK-STAT 1 2012 292
10. For recent reviews, see: K.S. Siveen, S. Sikka, R. Surana, X. Dai, J. Zhang, A.P. Kumar, B.K.H. Tan, G. Sethi, and A. Bishayee Biochim. Biophys. Acta 2014 1845 136
11. X. Wang, P.J. Crowe, D. Goldstein, and J.-L. Yang Int. J. Oncol. 41 2012 1181
12. P.K. Mandal, F. Gao, Z. Lu, Z. Ren, R. Ramesh, J.S. Birtwistle, K.K. Kaluarachchi, X. Chen, R.C. Bast Jr., W. Liao, and J.S. McMurray J. Med. Chem. 54 2011 3549
13. J. Chen, L. Bai, D. Bernard, Z. Nikolovska-Coleska, C. Gomez, J. Zhang, H. Yi, and S. Wang ACS Med. Chem. Lett. 1 2010 85
14. S. Haftchenary, H.A. Luchman, A.O. Jouk, A.J. Veloso, B.D.G. Page, X.R. Cheng, S.S. Dawson, N. Grinshtein, V.M. Shahani, K. Kerman, D.R. Kaplan, C. Griffin, A.M. Aman, R. Al-awar, S. Weiss, and P.T. Gunning ACS Med. Chem. Lett. 4 2013 1102
15. L. Pedranzini, T. Dechow, M. Berishaj, R. Comenzo, P. Zhou, J. Azare, W. Bornmann, and J. Bromberg Cancer Res. 66 2006 9714
16. K. Swiatek-Machado, J. Mieczkowski, A. Ellert-Miklaszewska, P. Swierk, I. Fokt, S. Szymanski, S. Skora, W. Szeja, G. Grynkiewicz, B. Lesyng, W. Priebe, and B. Kaminska Canc. Biol. Ther. 13 2012 657
17. F. Yang, V. Jove, R. Buettner, H. Xin, J. Wu, Y. Wang, S. Nam, Y. Xu, T. Ara, Y.A. DeClerck, R. Seeger, H. Yu, and R. Jove Cancer Biol. Ther. 13 2012 534
18. F. Hayakawa, K. Sugimoto, Y. Harada, N. Hashimoto, N. Ohi, and T. Naoe Blood Cancer J. 3 2013 e166
19. M.-J. Kim, H.-J. Nam, H.-P. Kim, S.-W. Han, S.-A. Im, T.-Y. Kim, D.-Y. Oh, and Y.-J. Bang Cancer Lett. 335 2013 145
20. P.A. Johnston, M. Sen, Y. Hua, D. Camarco, T.Y. Shun, J.S. Lazo, and J.R. Grandis Assay Drug Dev. Technol. 12 2014 55
21. G.A. Holloway, W.N. Charman, A.J. Fairlamb, R. Brun, M. Kaiser, E. Kostewicz, P.M. Novellow, J.P. Parisot, J. Richardson, I.P. Street, K.G. Watson, and J.B. Baell Antimicrob. Agents Chemother. 53 2009 2824
22. M. Ciustea, J.E.Y. Silverman, A.M.D. Shudofsky, and R.P. Ricciardi J. Med. Chem. 51 2008 6563
23. T.R. Webb, D. Lvovskiy, S.-A. Kim, X.-D. Ji, N. Melman, J. Linden, and K.A. Jacobson Bioorg. Med. Chem. 11 2003 77
24. Pubchem (http://pubchem.ncbi.nlm.nih.gov) activity for 11a indicates 21 active assays (6-confirmatory) in 666 bioassays tested: Down Regulation Insulin Promoter (AID 1628); Cytotoxicity MIN6 cells (AID 2122); Cruzain Inhibition (AIDs 1476, 1478); FEN1 Endonuclease inhibition (AIDs 588795, 720498).
25. C.A. Lipinski, F. Lombardo, B.W. Dominy, and P.J. Feeney Adv. Drug Delivery Rev. 23 1997 3
26. D.F. Veber, S.R. Johnson, H.-Y. Cheng, B.R. Smith, K.W. Ward, and K.D. Kopple J. Med. Chem. 45 2002 2615
27. Physicochemical Properties were Calculated Using: Maestro 8.5.207-QikProp 2.1, Schrödinger, LLC: New York, NY, USA.
28. K.S. Shikhaliev, A.V. Falaleev, G.I. Ermolova, and A.S. Solov'ev Chem. Heterocycl. Compd. 38 2002 210
29. J. Fotie, M. Kaiser, D.A. Delfin, J. Manley, C.S. Reid, J.-M. Paris, T. Wenzler, L. Maes, K.V. Mahasenan, C. Li, and K.A. Werbovetz J. Med. Chem. 53 2010 966 and references cited therein
30. J.P. Brown J. Chem. Soc. 1964 3012
31. R. Arienzo, S. Cramp, H.J. Dyke, P.M. Lockey, D. Norman, A.G. Roach, P. Smith, M. Wong, and S.P. Wren Bioorg. Med. Chem. Lett. 17 2007 1403
32. W.L.F. Armarego, and J.I.C. Smith J. Chem. Soc. 1966 234
33. K.S. Shikhaliev, A.V. Falaleev, D.V. Krylsky, A.S. Solov'ev, and G.V. Shatalov Chem. Heterocycl. Compd. 38 2002 1368
34. J. Guiles, X. Sun, I.A. Critchley, U. Ochsner, M. Tregay, K. Stone, J. Bertino, L. Green, R. Sabin, F. Dean, H.G. Dallmann, C.S. McHenry, and N. Janjic Bioorg. Med. Chem. Lett. 19 2009 800